The decrease in apoptosis protein and cell apoptosis rate indicated that NLRP3 was involved in CI-AKI injury, and that rosiglitazone could activate PPARγ to down-regulate the expression of NLRP3, effectively reducing the occurrence of cell apoptosis and achieving a certain therapeutic effect. Here, NLRP3 is linked to acute kidney injury.